Charles Schwab Investment Management Inc. Boosts Position in Janux Therapeutics, Inc. $JANX

Charles Schwab Investment Management Inc. lifted its stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 0.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 273,643 shares of the company’s stock after acquiring an additional 508 shares during the period. Charles Schwab Investment Management Inc. owned 0.46% of Janux Therapeutics worth $7,388,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of JANX. Wells Fargo & Company MN raised its holdings in Janux Therapeutics by 52.9% in the 4th quarter. Wells Fargo & Company MN now owns 13,251 shares of the company’s stock valued at $709,000 after buying an additional 4,585 shares during the period. First Trust Advisors LP purchased a new stake in Janux Therapeutics in the 4th quarter valued at about $6,856,000. MetLife Investment Management LLC raised its holdings in Janux Therapeutics by 5.8% in the 4th quarter. MetLife Investment Management LLC now owns 17,298 shares of the company’s stock valued at $926,000 after buying an additional 949 shares during the period. Teachers Retirement System of The State of Kentucky purchased a new stake in Janux Therapeutics in the 4th quarter valued at about $653,000. Finally, Tower Research Capital LLC TRC raised its holdings in Janux Therapeutics by 878.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,827 shares of the company’s stock valued at $205,000 after buying an additional 3,436 shares during the period. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on JANX shares. Raymond James Financial started coverage on shares of Janux Therapeutics in a report on Friday, July 11th. They issued an “outperform” rating and a $65.00 price objective on the stock. Piper Sandler started coverage on shares of Janux Therapeutics in a report on Monday, August 18th. They issued an “overweight” rating and a $42.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $86.90.

Janux Therapeutics Price Performance

NASDAQ JANX opened at $23.64 on Wednesday. The company has a market cap of $1.42 billion, a P/E ratio of -13.13 and a beta of 2.86. The stock has a 50-day moving average of $24.52 and a two-hundred day moving average of $27.44. Janux Therapeutics, Inc. has a 1-year low of $21.97 and a 1-year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Thursday, August 7th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.07). On average, analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.